Emergent Biosolutions Inc.
EBS Healthcare Drug Manufacturers Specialty & Generic
Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.
Follow EBS
Emergent Biosolutions Inc. (EBS) P/E ratio
Emergent Biosolutions Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 738× (November 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 13.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 10.0× | (35.24%) |
| FY2020 | 15.5× | (69.54%) |
| FY2019 | 50.9× | 7.32% |
| FY2018 | 47.4× | 92.78% |
| FY2017 | 24.6× | (14.87%) |
| FY2016 | 28.9× | 15.55% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 13.0× | 107.99% |
| Sep 2025 | 6.3× | 155.90% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. | n/m |
| TKNO Alpha Teknova, Inc. compare | n/m |
| AQST Aquestive Therapeutics, Inc. compare | n/m |
| EVO Evotec AG compare | n/m |
| TLRY Tilray Brands, Inc. compare | n/m |
| EOLS Evolus, Inc. compare | n/m |
| ANIK Anika Therapeutics Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| KMDA Kamada Ltd. compare | 20.4× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)